Literature DB >> 8921954

Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma.

B Bogen1.   

Abstract

Tumors could escape an immune attack by inducing peripheral T cell tolerance. To test this, T cell receptor (TCR)-transgenic mice were injected with plasmacytoma cells secreting a highly tumor-specific antigen, a monoclonal immunoglobulin (Ig), for which the transgene-encoded TCR is specific. The TCR recognizes a third hypervariable region idiotypic (Id) peptide of the Ig, presented by a class II molecule on host antigen-presenting cells. The TCR-transgenic mice have previously been shown to be protected against an Id+ plasmacytoma challenge. In the present experiments, the protection was deliberately overwhelmed by subcutaneous injection of large numbers of plasmacytoma cells. Such tumor mice, chronically exposed to increasing amounts of monoclonal Ig, delete Id-specific CD4+ T cells in their peripheral lymphoid organs and in the tumor. The residual CD4+ cells express endogenous, rather than transgene-encoded TCR alpha chains. Peripheral deletion, functional T cells unresponsiveness, and thymocyte deletion are all first detected at the same serum concentration of monoclonal Ig, approximately 50 micrograms/ml (0.3 microM), and become more and more profound as the tumor burden increases. The results suggest that peripheral T cell tolerance to Id could be a tumor escape mechanism in patients with B cell malignancies. In addition, the findings have implications for T cell tolerance to Ig V regions in normal individuals.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8921954     DOI: 10.1002/eji.1830261119

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  37 in total

1.  Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.

Authors:  Z Dembic; K Schenck; B Bogen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

2.  Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis.

Authors:  Marianne A Mihalyo; Adam T Hagymasi; Aaron M Slaiby; Erin E Nevius; Adam J Adler
Journal:  Prostate       Date:  2007-04-01       Impact factor: 4.104

3.  Induction of antigen-specific T cell anergy: An early event in the course of tumor progression.

Authors:  K Staveley-O'Carroll; E Sotomayor; J Montgomery; I Borrello; L Hwang; S Fein; D Pardoll; H Levitsky
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

4.  Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells.

Authors:  Sergei Kusmartsev; Srinivas Nagaraj; Dmitry I Gabrilovich
Journal:  J Immunol       Date:  2005-10-01       Impact factor: 5.422

5.  Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

Authors:  Charles G Drake; Amy D H Doody; Marianne A Mihalyo; Ching-Tai Huang; Erin Kelleher; Sowmya Ravi; Edward L Hipkiss; Dallas B Flies; Eugene P Kennedy; Meixiao Long; Patrick W McGary; Lee Coryell; William G Nelson; Drew M Pardoll; Adam J Adler
Journal:  Cancer Cell       Date:  2005-03       Impact factor: 31.743

6.  T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells.

Authors:  Madhav V Dhodapkar; Joseph Krasovsky; Kara Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-16       Impact factor: 11.205

Review 7.  Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer.

Authors:  Julie R Brahmer; Drew M Pardoll
Journal:  Cancer Immunol Res       Date:  2013-07-22       Impact factor: 11.151

8.  In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy.

Authors:  Marianne A Mihalyo; Amy D H Doody; Jeremy P McAleer; Elizabeth C Nowak; Meixiao Long; Yi Yang; Adam J Adler
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

9.  Induction of type I IFN is required for overcoming tumor-specific T-cell tolerance after stem cell transplantation.

Authors:  Ian Horkheimer; Michael Quigley; Jiangao Zhu; Xiaopei Huang; Nelson J Chao; Yiping Yang
Journal:  Blood       Date:  2009-03-11       Impact factor: 22.113

Review 10.  Cancer and the Immune System: Basic Concepts and Targets for Intervention.

Authors:  Drew Pardoll
Journal:  Semin Oncol       Date:  2015-06-03       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.